What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.
Overview
Lori Anne Kunkel, Director of Enliven Therapeutics (NASDAQ:ELVN), reported the sale of 10,000 shares of common stock for a total consideration of approximately $345,000 on June 5, 2026, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($34.54); post-transaction value based on June 5, 2026 market close.
Details
Enliven Therapeutics is a Boulder-based biotechnology company specializing in the discovery and clinical development of novel small-molecule therapies for cancer. With a lean workforce and a focus on kinase inhibitors, the company aims to address high-value oncology indications with significant unmet need. Enliven’s competitive edge lies in its targeted approach and advancement of differentiated assets in early-stage clinical trials.
Source
Originally published at www.fool.com.